Market Assessment
Gilead (GILD) is a large cap ($88B) biopharmaceutical known for its pioneering innovative therapeutics for viral liver diseases. Gilead started 2019 with the clinical failures of selonsertib in Phase 3 NASH. As one of the Phase 3 clinical favorites for NASH, the two recent clinical failures of selonsertib in monotherapy Phase 3 NASH fibrosis and compensated cirrhotic NASH trials may have revealed the complex pathophysiology of NASH disease. It reinforces the need for ongoing clinical development of investigative drug candidates with distinct pharmacological and mechanistic targets for NASH disease due to the multi-faceted